In a cohort unselected by age of 275 osteosarcomas arising in the bone (age range: 4–64 years), FGFR1 amplification was detected in 24 (~10%) patients, including paediatric patients, and was disproportionately present in the rarer histological variants and associated with poor response to chemotherapy [43]. This evidence concerns the gene FGFR1 and osteosarcoma.